Johnson & Johnson (NYSE:JNJ) Receives $192.94 Consensus PT from Analysts

Johnson & Johnson (NYSE:JNJ) has received an average rating of “Moderate Buy” from the twenty-two analysts that are presently covering the stock, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation, twelve have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $199.5882.

JNJ has been the topic of a number of research reports. Barclays upped their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. UBS Group upped their price target on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research note on Tuesday. The Goldman Sachs Group upped their price target on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus upped their price target on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research note on Wednesday.

Johnson & Johnson Trading Up 0.3%

Shares of Johnson & Johnson stock opened at $191.79 on Tuesday. The firm has a market capitalization of $461.90 billion, a price-to-earnings ratio of 18.51, a PEG ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a 50 day moving average of $180.09 and a 200 day moving average of $164.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

Several hedge funds have recently modified their holdings of the stock. Castle Rock Wealth Management LLC raised its stake in shares of Johnson & Johnson by 1.7% in the third quarter. Castle Rock Wealth Management LLC now owns 4,895 shares of the company’s stock valued at $910,000 after acquiring an additional 84 shares in the last quarter. Columbus Macro LLC raised its stake in shares of Johnson & Johnson by 0.8% in the third quarter. Columbus Macro LLC now owns 35,715 shares of the company’s stock valued at $6,622,000 after acquiring an additional 300 shares in the last quarter. Mezzasalma Advisors LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at $222,000. Hengehold Capital Management LLC raised its stake in shares of Johnson & Johnson by 2.2% in the third quarter. Hengehold Capital Management LLC now owns 26,684 shares of the company’s stock valued at $4,948,000 after acquiring an additional 585 shares in the last quarter. Finally, Lockerman Financial Group Inc. acquired a new stake in shares of Johnson & Johnson in the third quarter valued at $207,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.